Pan-cancer analysis of UDP-glucose 6-dehydrogenase in human tumors and its function in hepatocellular carcinoma

doi:10.4251/wjgo.v17.i7.105981

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 7

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (0)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-11) series.

Item

Count

PDF

HTML

Figures (1-11)

Sum=0

Jul 15, 2025 (publication date) through Jul 14, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Gastrointest Oncol. Jul 15, 2025; 17(7): 105981
Published online Jul 15, 2025. doi: 10.4251/wjgo.v17.i7.105981

Pan-cancer analysis of UDP-glucose 6-dehydrogenase in human tumors and its function in hepatocellular carcinoma

Xu Cao, Shi-Hao Zheng, Jiu-Mei Shen, Si-Ze Li, Li Hou, Jia-Xin Zhang, Xiao-Ke Li, Hong-Bo Du, Li-Ping Zhang, Yong-An Ye, Xiao-Bin Zao

Xu Cao, Shi-Hao Zheng, Si-Ze Li, Jia-Xin Zhang, Xiao-Ke Li, Hong-Bo Du, Li-Ping Zhang, Yong-An Ye, Department of Spleen and Gastroenterology, Dongzhimen Hospital of Beijing University of Chinese Medicine, Beijing 100700, China

Xu Cao, Department of Gastroenterology, The First Affiliated Hospital of Dalian Medical University, Dalian 116000, Liaoning Province, China

Jiu-Mei Shen, Department of Pathology, Xiamen Hospital of Chinese Medicine, Xiamen 361000, Fujian Province, China

Li Hou, Department of Oncology and Hematology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100029, China

Jia-Xin Zhang, Xiao-Ke Li, Hong-Bo Du, Yong-An Ye, Institute of Liver Diseases, Beijing University of Chinese Medicine, Beijing 100700, China

Xiao-Bin Zao, Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China

Xiao-Bin Zao, Ministry of Science, Xiamen Hospital of Chinese Medicine, Xiamen 361000, Fujian Province, China

Co-first authors: Xu Cao and Shi-Hao Zheng.

Co-corresponding authors: Yong-An Ye and Xiao-Bin Zao.

Author contributions: Cao X and Zheng SH made equal contributions to performing experiments, data analysis, and writing of the manuscript; Shen JM contributed to clinical sample collection, experiments, and data analysis; Li SZ, Hou L, Zhang JX, and Li XK collected and analyzed data; Du HB and Zhang LP validated the data analysis; Cao X and Zheng SH contributed equally to this work as co-first authors. Zao XB and Ye YA designed the research, performed data analysis, contributed to the conceptualization of the paper, revised the manuscript, and worked together to ensure the smooth progress of the study; therefore, they are designated as co-corresponding authors.

Supported by National Natural Science Foundation of China, No. 82405314; Horizontal Project of Dongzhimen Hospital, No. HX-DZM-202405; Project of Beijing University of Chinese Medicine, No. DZMG-QNZX-24015; and Traditional Chinese Medicine Foundation of Xiamen, No. XWZY-2023-0616.

Institutional review board statement: The Ethics Committee of Xiamen Hospital of Traditional Chinese Medicine approved the investigation of clinical samples (2020-K030-01).

Institutional animal care and use committee statement: The Ethics Committee of Laboratory Animals of Dongzhimen Hospital of Beijing University of Chinese Medicine approved the animal study (No. 21-10-01 and 21-46-01).

Conflict-of-interest statement: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.

Data sharing statement: Not applicable.

Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Xiao-Bin Zao, PhD, Assistant Professor, Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Dongzhimen Hospital, Beijing University of Chinese Medicine, No. 116 Cuiping West Road, Tongzhou District, Beijing 100700, China. a3417@bucm.edu.cn

Received: February 14, 2025
Revised: March 26, 2025
Accepted: May 21, 2025
Published online: July 15, 2025
Processing time: 151 Days and 23.8 Hours

Core Tip

Core Tip: Our study identified UDP-glucose 6-dehydrogenase (UGDH) as a potential prognostic biomarker and therapeutic target for many cancers, especially liver and lung cancer. UGDH promotes hepatocellular carcinoma cell proliferation, possibly by modulating the pentose and glucuronate interconversion pathway.